Cleo Diagnostics Ltd (ASX:COV)

Theseus Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023
Net Income	-3.1	-3.76	-1.73
Depreciation & Amortization	0.06	0.06	0.04
Stock-Based Compensation	1.5	1.5	0.78
Other Operating Activities	-1.6	-0.17	0
Change in Accounts Receivable	-0.01	-0.01	-0.03
Change in Accounts Payable	0.02	0.02	0.37
Change in Other Net Operating Assets	0.33	0.33	-0.12
Operating Cash Flow	-2.79	-2.03	-0.68
Capital Expenditures	-0	-0	-0.04
Sale (Purchase) of Intangibles	-	-	-0.3
Investing Cash Flow	-0	-0	-0.34
Short-Term Debt Issued	-	-	1.6
Total Debt Issued	-	-	1.6
Short-Term Debt Repaid	-	-	-0.2
Total Debt Repaid	-	-	-0.2
Net Debt Issued (Repaid)	-	-	1.4
Issuance of Common Stock	-	12	-
Other Financing Activities	0	-0.83	-0.18
Financing Cash Flow	0	11.17	1.22
Net Cash Flow	-2.8	9.13	0.2
Free Cash Flow	-2.8	-2.03	-0.72
Free Cash Flow Margin	-1326.90%	-964.47%	-
Free Cash Flow Per Share	-0.03	-0.02	-0.03
Levered Free Cash Flow	-0.2	-0.4	-
Unlevered Free Cash Flow	-0.2	-0.38	-
Change in Net Working Capital	-0.24	-0.34	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.